Biotech
OBI Pharma
Pipelines & Platforms
OBI Pharma develops innovative cancer therapies to improve patients’ outcomes
and quality of life. We advance first- and best-in-class antibody-drug conjugates targeting TROP2, Nectin4, HER2, and
dual antigens, supported by proprietary
ADC technologies including GlycOBI®, ThiOBI®, EndoSymeOBI®, HYPrOBI® and GlycOBI DUO®.
Interests
- Out-Licensing
- Strategic Alliance
Contact Information
- NameJukka Muhonen / Celeste Chuang Michelle Yang / Tammy Wu
- PositionExecutive Director of Business Development,Director of Business Development, Director of Business Development, Senior Specialist of Business Development
- Tel
- www.obipharma.com